Celcuity price target raised to $141 from $108 at Craig-Hallum

Craig-Hallum raised the firm’s price target on Celcuity (CELC) to $141 from $108 and keeps a Buy rating on the shares following the Q4 update, which was largely in line and focused on pipeline progress. Management reiterated confidence in the wild-type NDA filing, which the firm shares given the strength of the data. Attention now shifts to the VIKTORIA-1 mutant cohort readout, now expected in Q2, with management declining to comment given proximity to data. Craig-Hallum views the timing as consistent with slower event accrual, similar to wild-type, which was the result of geda patients doing better.